Invited Editorials
15 April 2022
Vol. 1 No. 1 (2022)
https://doi.org/10.4081/btvb.2022.22

Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Milvexian, Anti-XI agents, Venous thromboembolism
1999
Views
525
Downloads

Authors

Marco P. Donadini
marcopaolo.donadini@uninsubria.it
Research Center on Thromboembolic Diseases and Antithrombotic Therapies, Department of Medicine and Surgery, University of Insubria, Varese; Thrombosis and Hemostasis Center, Ospedale di Circolo e Fondazione Macchi, Azienda Socio-Sanitaria territoriale dei Sette Laghi, Varese, Italy.
Walter Ageno
Research Center on Thromboembolic Diseases and Antithrombotic Therapies, Department of Medicine and Surgery, University of Insubria, Varese; Thrombosis and Hemostasis Center, Ospedale di Circolo e Fondazione Macchi, Azienda Socio-Sanitaria territoriale dei Sette Laghi, Varese, Italy.

For almost 90 years, the discovery and development of anticoagulant drugs have focused on maximizing their antithrombotic efficacy while minimizing the risk of bleeding, in addition to providing manageable compounds with predictable and/or monitorable effects [...].

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Sanghai S, Wong C, Wang Z, et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: The SAGE-AF Study. J Am Heart Assoc 2020;9:e014108. DOI: https://doi.org/10.1161/JAHA.119.014108
Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017;117:382-9. DOI: https://doi.org/10.1160/TH16-07-0494
Hsu C, Hutt E, Bloomfield DM, et al. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol 2021;78:625-31. DOI: https://doi.org/10.1016/j.jacc.2021.06.010
Fredenburgh JC, Weitz JI. New anticoagulants: Moving beyond the direct oral anticoagulants. J Thromb Haemost. 2021 Dec 30. doi: 10.1111/jth.15631 DOI: https://doi.org/10.1111/jth.15126
Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015;372:232-40. DOI: https://doi.org/10.1056/NEJMoa1405760
Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the foxtrot randomized clinical trial. JAMA 2020;323:130-9. DOI: https://doi.org/10.1001/jama.2019.20687
Verhamme P, Yi BA, Segers A, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med 2021;385:609-17. DOI: https://doi.org/10.1056/NEJMoa2105872
Weitz JI, Strony J, Ageno W, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med 2021;385:2161-72. DOI: https://doi.org/10.1056/NEJMoa2113194
Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 2021;138:2173-84. DOI: https://doi.org/10.1182/blood.2021011725

How to Cite



Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?. (2022). Bleeding, Thrombosis and Vascular Biology, 1(1). https://doi.org/10.4081/btvb.2022.22
Copyright (c) 2022 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.